5AM Venture Management LLC Has $8.34 Million Stake in Biohaven Ltd. $BHVN

5AM Venture Management LLC lifted its stake in Biohaven Ltd. (NYSE:BHVN) by 54.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 738,972 shares of the company’s stock after purchasing an additional 260,000 shares during the quarter. Biohaven comprises 2.6% of 5AM Venture Management LLC’s investment portfolio, making the stock its 15th largest position. 5AM Venture Management LLC’s holdings in Biohaven were worth $8,343,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. ACT Capital Management LLC acquired a new stake in Biohaven during the 4th quarter worth $85,000. Freestone Grove Partners LP acquired a new stake in Biohaven during the 4th quarter worth $290,000. Schonfeld Strategic Advisors LLC raised its holdings in Biohaven by 3,829.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 1,606,777 shares of the company’s stock worth $18,141,000 after purchasing an additional 1,565,891 shares during the period. Burkehill Global Management LP acquired a new stake in Biohaven in the fourth quarter worth $5,645,000. Finally, PDT Partners LLC acquired a new position in shares of Biohaven in the 4th quarter valued at $956,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Trading Up 13.2%

Shares of NYSE:BHVN opened at $13.69 on Thursday. The company’s 50-day moving average price is $10.18 and its two-hundred day moving average price is $10.57. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41. Biohaven Ltd. has a one year low of $7.48 and a one year high of $18.57. The stock has a market capitalization of $2.06 billion, a PE ratio of -2.41 and a beta of 1.35.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, equities analysts forecast that Biohaven Ltd. will post -3.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BHVN. Citigroup boosted their price target on shares of Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Wall Street Zen lowered shares of Biohaven from a “sell” rating to a “strong sell” rating in a report on Sunday, April 26th. Canaccord Genuity Group began coverage on shares of Biohaven in a report on Monday, April 13th. They issued a “buy” rating and a $21.00 price target for the company. Morgan Stanley decreased their price target on shares of Biohaven from $21.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 price objective on shares of Biohaven in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Biohaven currently has an average rating of “Moderate Buy” and a consensus price target of $22.27.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.